ImmunityBio (IBRX) Cash & Equivalents (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Cash & Equivalents data on file, last reported at $205.2 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 238.27% year-over-year to $205.2 million in Q1 2026; TTM through Mar 2026 was $205.2 million, a 238.27% increase from a year earlier, with the FY2025 full-year figure at $88.3 million, down 38.41% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $205.2 million, up from $88.3 million in the prior quarter.
• Over the last five years, Cash & Equivalents for IBRX reached as high as $265.5 million in Q4 2023 and fell as low as $36.4 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $114.9 million across 5 years, with a median of $104.6 million in 2022.
• Across the five-year window, Cash & Equivalents slumped 54.4% in 2025 and surged 238.27% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $104.6 million in 2022, then soared by 153.68% to $265.5 million in 2023, then slumped by 45.97% to $143.4 million in 2024, then plunged by 38.41% to $88.3 million in 2025, then surged by 132.29% to $205.2 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $205.2 million in Q1 2026, $88.3 million in Q4 2025, and $60.2 million in Q3 2025.